HOME >> MEDICINE >> NEWS
The National Comprehensive Cancer Network recognizes National Cancer Fatigue Awareness Day

ROCKLEDGE, PA, April 3, 2002 In its continuing effort to improve care for cancer patients, the National Comprehensive Cancer Network (NCCN) recently announced the release of its new Cancer and Treatment-Related Anemia Practice Guidelines for physicians and its Cancer-Related Fatigue Treatment Guidelines for Patients.

The NCCN Cancer and Treatment-Related Anemia Guidelines were developed to assist clinicians in making decisions about when and how to treat cancer and treatment-related anemia. In particular, these guidelines focus on the type of anemia associated with chronic disease and review the available data guiding the use of erythropoietin in these patients. said Paul Sabbatini, MD, Assistant Attending Physician in the Developmental Chemotherapy Service at Memorial Sloan-Kettering Cancer Center and chairman of the NCCN Anemia Guidelines Panel.

Anemia may be caused by a variety of factors. In cancer patients, it often occurs in the setting of normal serum iron levels and is associated with inappropriately low serum erythropoietin production. Symptoms of anemia in patients range from shortness of breath, rapid heartbeat, and dizziness to inability to concentrate, weakness and fatigue. Available data support the concept that fatigue in patients with cancer is a multifactorial entity, and anemia represents a treatable subset of a very complex problem. Prior to the development of erythropoietin, the only way to treat patients with cancer and treatment-related anemia was with transfusion. The availability of erythropoietin provides a transfusion alternative in certain settings, and provides the ability to maintain hemoglobin in the normal range.

The NCCN guidelines recommend that patients with hemoglobin levels of < 11 g/dl enter the screening portion of the algorithm. If immediate correction with transfusion is not necessary, the pathways guide the clinician through an assessment of the potential risk of requiring transfusion, as well as an
'"/>

Contact: Todd Ringler
617-577-8110
Feinstein Kean Healthcare
3-Apr-2002


Page: 1 2

Related medicine news :

1. National Academies advisory: May 2 Symposium on International Science Policy
2. National Academies News: William H. Foege to receive Public Welfare Medal, Academys highest honor
3. National Academies news: Academy honors 17 for major contributions to science
4. National Academies advisory: Report assesses health implications of perchlorate exposure
5. National Academies Advisory: Jan. 11 public briefing on perchlorate in drinking water
6. National Academies news: Gulf War and Health
7. National survey shows few physicians elected to Congress
8. Six new Roybal Centers for Applied Gerontology established by National Institute on Aging
9. UGA professor receives $3 million grant from National Cancer Institute for breast cancer research
10. National Academies advisory: Nov. 4-6 Frontiers of Science meeting in Irvine, Calif.
11. National Chemistry Week celebrates health and wellness in Washington, D.C., area

Post Your Comments:
(Date:12/10/2013)... Urban Digital Magazine launches 360° multimedia ... launched its newly developed photo-sharing app, which provides a ... Cynthia Bailey at bar One in Atlanta on Monday, ... tagged with a branded hashtag as well as engages ... unique experience directly on their mobile device. , “Our ...
(Date:12/10/2013)... The top 7 anti-aging foods for people over ... Joel Marion provides information foods that are loaded with the ... can turn back the clock by following the anti-aging recommendations ... The new article posted on Health News Wires details 7 ... designed to support healthy hair and skin and protect ...
(Date:12/10/2013)... Rankingbyseo.com, one of the fastest growing ... SEO packages . The company has announced these ... Now, the Basic SEO package will cost $225; the ... cost $799; and the Enterprise package will cost $1499. ... research on the current marketing trend in online business ...
(Date:12/10/2013)... Plano, TX & Pleasanton, CA (PRWEB) December 10, 2013 ... groups and other professional providers continue to lose revenue ... the low focus hospitals put toward 1500 billing as ... of most physician billing systems. The problem of revenue ... hospitals accelerated acquisition of physician practices, making the need ...
(Date:12/10/2013)... Dr. Daniel T. Morof of Cherry Hill Dental Center ... finally achieve a healthy, permanent smile. By providing dental implants ... who rely on dentures as a result of tooth loss, ... smile. , “Everybody deserves a wonderful smile, and they ... said Dr. Daniel Morof, dental implants dentist in Garden City, ...
Breaking Medicine News(10 mins):Health News:Rolling Out Releases Photo-Sharing App with Cynthia Bailey During Cover Party Multimedia Platform 2Health News:Top 7 Anti-Aging Foods For People Over 40 Article Released By Health News Wires 2Health News:Rankingbyseo.com Announced Changes in Its SEO Packages 2Health News:GAFFEY Healthcare Announces Next Generation Professional Billing Solution 2Health News:Garden City, MI Cosmetic Dentist Dr. Daniel T. Morof Introduces Dental Implants as Best Alternative for Denture Wearers 2
(Date:12/10/2013)... growth in the United States will continue in ... executives in their December 2013 Semiannual Economic Forecast. ... recovery that began in mid-2009, as indicated in ... ® . The manufacturing sector is optimistic about ... in 16 manufacturing industries, and the non-manufacturing sector ...
(Date:12/10/2013)... 10, 2013   Upsher-Smith Laboratories, Inc. ... 1 data showing that USL255 (extended-release topiramate) may ... difficulty swallowing whole capsules or tablets.  Additionally, simulations ... a return to steady-state topiramate levels within one ... up to 18 hours, the risk of dropping ...
(Date:12/10/2013)... YORK, Dec. 10, 2013 Reportlinker.com ... is available in its catalogue: ... http://www.reportlinker.com/p01374859/Global-Carotenoids-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Synthetic_Dye_and_Pigment This report ... both US$ Million and Tons by the ... Annatto, Capsanthin, and Other Carotenoids. The major ...
Breaking Medicine Technology:Economic Growth Continues In 2014; Manufacturing Growth Expected in 2014; Revenue to Increase 4.4%; Capital Expenditures to Increase 8.0%; Capacity Utilization Currently at 80.3%; Non-Manufacturing Growth Projected in 2014; Revenue to Increase 3.6%; 2Economic Growth Continues In 2014; Manufacturing Growth Expected in 2014; Revenue to Increase 4.4%; Capital Expenditures to Increase 8.0%; Capacity Utilization Currently at 80.3%; Non-Manufacturing Growth Projected in 2014; Revenue to Increase 3.6%; 3Economic Growth Continues In 2014; Manufacturing Growth Expected in 2014; Revenue to Increase 4.4%; Capital Expenditures to Increase 8.0%; Capacity Utilization Currently at 80.3%; Non-Manufacturing Growth Projected in 2014; Revenue to Increase 3.6%; 4Economic Growth Continues In 2014; Manufacturing Growth Expected in 2014; Revenue to Increase 4.4%; Capital Expenditures to Increase 8.0%; Capacity Utilization Currently at 80.3%; Non-Manufacturing Growth Projected in 2014; Revenue to Increase 3.6%; 5Economic Growth Continues In 2014; Manufacturing Growth Expected in 2014; Revenue to Increase 4.4%; Capital Expenditures to Increase 8.0%; Capacity Utilization Currently at 80.3%; Non-Manufacturing Growth Projected in 2014; Revenue to Increase 3.6%; 6Economic Growth Continues In 2014; Manufacturing Growth Expected in 2014; Revenue to Increase 4.4%; Capital Expenditures to Increase 8.0%; Capacity Utilization Currently at 80.3%; Non-Manufacturing Growth Projected in 2014; Revenue to Increase 3.6%; 7Economic Growth Continues In 2014; Manufacturing Growth Expected in 2014; Revenue to Increase 4.4%; Capital Expenditures to Increase 8.0%; Capacity Utilization Currently at 80.3%; Non-Manufacturing Growth Projected in 2014; Revenue to Increase 3.6%; 8Economic Growth Continues In 2014; Manufacturing Growth Expected in 2014; Revenue to Increase 4.4%; Capital Expenditures to Increase 8.0%; Capacity Utilization Currently at 80.3%; Non-Manufacturing Growth Projected in 2014; Revenue to Increase 3.6%; 9Economic Growth Continues In 2014; Manufacturing Growth Expected in 2014; Revenue to Increase 4.4%; Capital Expenditures to Increase 8.0%; Capacity Utilization Currently at 80.3%; Non-Manufacturing Growth Projected in 2014; Revenue to Increase 3.6%; 10Economic Growth Continues In 2014; Manufacturing Growth Expected in 2014; Revenue to Increase 4.4%; Capital Expenditures to Increase 8.0%; Capacity Utilization Currently at 80.3%; Non-Manufacturing Growth Projected in 2014; Revenue to Increase 3.6%; 11Economic Growth Continues In 2014; Manufacturing Growth Expected in 2014; Revenue to Increase 4.4%; Capital Expenditures to Increase 8.0%; Capacity Utilization Currently at 80.3%; Non-Manufacturing Growth Projected in 2014; Revenue to Increase 3.6%; 12Economic Growth Continues In 2014; Manufacturing Growth Expected in 2014; Revenue to Increase 4.4%; Capital Expenditures to Increase 8.0%; Capacity Utilization Currently at 80.3%; Non-Manufacturing Growth Projected in 2014; Revenue to Increase 3.6%; 13Economic Growth Continues In 2014; Manufacturing Growth Expected in 2014; Revenue to Increase 4.4%; Capital Expenditures to Increase 8.0%; Capacity Utilization Currently at 80.3%; Non-Manufacturing Growth Projected in 2014; Revenue to Increase 3.6%; 14Economic Growth Continues In 2014; Manufacturing Growth Expected in 2014; Revenue to Increase 4.4%; Capital Expenditures to Increase 8.0%; Capacity Utilization Currently at 80.3%; Non-Manufacturing Growth Projected in 2014; Revenue to Increase 3.6%; 15Economic Growth Continues In 2014; Manufacturing Growth Expected in 2014; Revenue to Increase 4.4%; Capital Expenditures to Increase 8.0%; Capacity Utilization Currently at 80.3%; Non-Manufacturing Growth Projected in 2014; Revenue to Increase 3.6%; 16Economic Growth Continues In 2014; Manufacturing Growth Expected in 2014; Revenue to Increase 4.4%; Capital Expenditures to Increase 8.0%; Capacity Utilization Currently at 80.3%; Non-Manufacturing Growth Projected in 2014; Revenue to Increase 3.6%; 17Economic Growth Continues In 2014; Manufacturing Growth Expected in 2014; Revenue to Increase 4.4%; Capital Expenditures to Increase 8.0%; Capacity Utilization Currently at 80.3%; Non-Manufacturing Growth Projected in 2014; Revenue to Increase 3.6%; 18Economic Growth Continues In 2014; Manufacturing Growth Expected in 2014; Revenue to Increase 4.4%; Capital Expenditures to Increase 8.0%; Capacity Utilization Currently at 80.3%; Non-Manufacturing Growth Projected in 2014; Revenue to Increase 3.6%; 19Economic Growth Continues In 2014; Manufacturing Growth Expected in 2014; Revenue to Increase 4.4%; Capital Expenditures to Increase 8.0%; Capacity Utilization Currently at 80.3%; Non-Manufacturing Growth Projected in 2014; Revenue to Increase 3.6%; 20Economic Growth Continues In 2014; Manufacturing Growth Expected in 2014; Revenue to Increase 4.4%; Capital Expenditures to Increase 8.0%; Capacity Utilization Currently at 80.3%; Non-Manufacturing Growth Projected in 2014; Revenue to Increase 3.6%; 21Economic Growth Continues In 2014; Manufacturing Growth Expected in 2014; Revenue to Increase 4.4%; Capital Expenditures to Increase 8.0%; Capacity Utilization Currently at 80.3%; Non-Manufacturing Growth Projected in 2014; Revenue to Increase 3.6%; 22Economic Growth Continues In 2014; Manufacturing Growth Expected in 2014; Revenue to Increase 4.4%; Capital Expenditures to Increase 8.0%; Capacity Utilization Currently at 80.3%; Non-Manufacturing Growth Projected in 2014; Revenue to Increase 3.6%; 23Economic Growth Continues In 2014; Manufacturing Growth Expected in 2014; Revenue to Increase 4.4%; Capital Expenditures to Increase 8.0%; Capacity Utilization Currently at 80.3%; Non-Manufacturing Growth Projected in 2014; Revenue to Increase 3.6%; 24Economic Growth Continues In 2014; Manufacturing Growth Expected in 2014; Revenue to Increase 4.4%; Capital Expenditures to Increase 8.0%; Capacity Utilization Currently at 80.3%; Non-Manufacturing Growth Projected in 2014; Revenue to Increase 3.6%; 25Economic Growth Continues In 2014; Manufacturing Growth Expected in 2014; Revenue to Increase 4.4%; Capital Expenditures to Increase 8.0%; Capacity Utilization Currently at 80.3%; Non-Manufacturing Growth Projected in 2014; Revenue to Increase 3.6%; 26Economic Growth Continues In 2014; Manufacturing Growth Expected in 2014; Revenue to Increase 4.4%; Capital Expenditures to Increase 8.0%; Capacity Utilization Currently at 80.3%; Non-Manufacturing Growth Projected in 2014; Revenue to Increase 3.6%; 27Economic Growth Continues In 2014; Manufacturing Growth Expected in 2014; Revenue to Increase 4.4%; Capital Expenditures to Increase 8.0%; Capacity Utilization Currently at 80.3%; Non-Manufacturing Growth Projected in 2014; Revenue to Increase 3.6%; 28Economic Growth Continues In 2014; Manufacturing Growth Expected in 2014; Revenue to Increase 4.4%; Capital Expenditures to Increase 8.0%; Capacity Utilization Currently at 80.3%; Non-Manufacturing Growth Projected in 2014; Revenue to Increase 3.6%; 29Economic Growth Continues In 2014; Manufacturing Growth Expected in 2014; Revenue to Increase 4.4%; Capital Expenditures to Increase 8.0%; Capacity Utilization Currently at 80.3%; Non-Manufacturing Growth Projected in 2014; Revenue to Increase 3.6%; 30Economic Growth Continues In 2014; Manufacturing Growth Expected in 2014; Revenue to Increase 4.4%; Capital Expenditures to Increase 8.0%; Capacity Utilization Currently at 80.3%; Non-Manufacturing Growth Projected in 2014; Revenue to Increase 3.6%; 31Economic Growth Continues In 2014; Manufacturing Growth Expected in 2014; Revenue to Increase 4.4%; Capital Expenditures to Increase 8.0%; Capacity Utilization Currently at 80.3%; Non-Manufacturing Growth Projected in 2014; Revenue to Increase 3.6%; 32Upsher-Smith Presents New Data On The PK Equivalence Of USL255 (Extended-Release Topiramate) When Sprinkled On Food Or Swallowed Intact 2Upsher-Smith Presents New Data On The PK Equivalence Of USL255 (Extended-Release Topiramate) When Sprinkled On Food Or Swallowed Intact 3Upsher-Smith Presents New Data On The PK Equivalence Of USL255 (Extended-Release Topiramate) When Sprinkled On Food Or Swallowed Intact 4Global Carotenoids Industry 2
Cached News: